Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 14, 2025 04:49 ET | Source: InnoCare Pharma

InnoCare Announces Achievement of Primary Endpoint in Phase IIb Study of Orelabrutinib for SLE and Approval of Phase III Clinical Trial

Orelabrutinib demonstrated outstanding efficacy and well-tolerated safety profile in patients with SLE who had received 48 weeks of treatment.
December 10, 2025 08:30 ET | Source: Journey Medical Corporation

Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology

Clinical trial achieved all three primary objectives with no significant safety issues being reported Results indicate that Emrosi can be safely used for up to 16 weeks with no detectable impact on...
November 28, 2025 00:28 ET | Source: SNS Insider pvt ltd

Atopic Dermatitis Drugs Market to Reach $29.43 Billion by 2032, Driven by Rising Disease Prevalence & Strong Therapeutic Innovation | SNS Insider

Austin, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Atopic Dermatitis Drugs Market Size & Growth Analysis According to by SNS Insider, the Atopic Dermatitis Drugs Market size was valued at USD 14.93...
November 27, 2025 20:55 ET | Source: InnoCare Pharma

InnoCare Announces First Patient Dosed in the Global Phase II Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Prurigo Nodularis

InnoCare's pipeline under development now covers ten major autoimmune diseases, with a particular focus on dermatological conditions.
November 25, 2025 01:00 ET | Source: Regeneron Pharmaceuticals, Inc.

Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)

Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are approximately 270,000 adults and adolescents aged 12 years...
November 20, 2025 07:58 ET | Source: BCC Research LLC

Global Hyaluronic Acid in Healthcare Market to Reach $10.5 Billion by 2030

Boston, Nov. 20, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, “Hyaluronic Acid in Healthcare: Global Markets” is projected to grow from $8 billion in 2025 to $10.5...
November 19, 2025 10:50 ET | Source: Research and Markets

Dermatology Collaboration and Licensing Agreements Analysis Report and Directory 2025: Upfront, Milestone, and Royalties for 476 Deals by Company A-Z, Therapy Focus and Technology Type

Dublin, Nov. 19, 2025 (GLOBE NEWSWIRE) -- The "Dermatology Collaboration and Licensing Deals 2016-2025" report has been added to ResearchAndMarkets.com's offering.Fully revised and updated, the...
November 18, 2025 04:05 ET | Source: Research and Markets

Vitiligo Market Analysis Report 2025-2035: Targeted Therapies Like Biologics, Oral Medications, and Advanced Topicals Bolster Growth

Dublin, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The "Vitiligo Market - A Global and Regional Analysis: Focus on Regional and Country Analysis - Analysis and Forecast, 2025-2035" report has been added to ...
November 12, 2025 16:01 ET | Source: Journey Medical Corporation

Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

Third quarter 2025 net revenues were $17.6 million Emrosi™ total prescriptions increased 146% over the second quarter of 2025 Emrosi net revenues were $4.9 million Company to hold conference call...
November 12, 2025 09:00 ET | Source: Mochi Health

Mochi Health Expands Beyond Obesity Care with Comprehensive Digital Health Platform, Adding 15 New Categories of Care

SAN FRANCISCO, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Mochi Health, an evidence-based medicine platform that connects patients with providers, today announced the strategic expansion of its digital...